Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivaltinostat Phase I MAD Study in Healthy Volunteers
NCT05716919Phase 1Active, not recruiting
- Sponsor
- Machaon Biotherapeutics
- Start
- Mar 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hematologic malignancy, solid tumor and fibrosis comparing Ivaltinostat Cohorts with Placebo (2 arms). Primary endpoints: Maximum Plasma Concentration up to 4 weeks and Area Under the Curve up to 4 weeks. Started Mar 2023; status: active, not recruiting.
02
Drugs
ivaltinostat
03
Conditions
hematologic malignancysolid tumorfibrosis
Beyond the preview
Go deeper on NCT05716919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05716919.